Search

Your search keyword '"Schouten, H C"' showing total 346 results
Start Over Author "Schouten, H C"
346 results on '"Schouten, H C"'

1. Late effecten na behandeling van kanker

Author

Loonen, J. J., Janssens, G. O. R. J., Kremer, L. C. M., Nuver, J., Schouten, H. C., van Krieken, J.H.J.M., editor, Beets-Tan, R.G.H., editor, Gelderblom, A.J., editor, Olofsen, M.J.J., editor, and Rutten, H.J.T., editor

Published
2020
Full Text
View/download PDF

2. Cognitive functioning in survivors of hematopoietic stem cell transplantation compared with a matched general population sample: The MOSA study

Author

Wauben, B., van der Poel, M. W. M., Greevenbroek, M. M. J., van Yperen, N. C., Schram, M. T., van Boxtel, M. P. J., Sastry, M., Simons, S. O., Stehouwer, C. D. A., Dagnelie, P. C., Wesselius, A., Schouten, H. C., Köhler, S., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: HVC Pieken Maastricht Studie (9), Psychology 2, Section Neuropsychology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: FPN NPPP I, RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), MUMC+: MA Interne Geneeskunde (3), RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, and Psychology 5

Abstract

BACKGROUND: Although cognitive problems can recover over time, a subgroup of hematopoietic stem cell transplantation (HCT) survivors experiences persistent cognitive problems in the long-term. Despite these implications, studies assessing cognitive functioning in HCT survivors are limited. OBJECTIVES: The aim of the present study was (1) to quantify the prevalence of cognitive impairment in patients treated with HCT who survived at least 2 years, and to compare these with a matched reference group representing the general population; (2) to identify potential determinants of cognitive functioning within the HCT survivor group. STUDY DESIGN: Within the single-centre Maastricht Observational study of late effects after Stem cell trAnsplantation (MOSA) cognitive performance was assessed by a neuropsychological test battery divided into three cognitive domains respectively memory, information processing speed, and executive function & attention. An overall cognition score was calculated as the average of the domain scores. A total of 115 HCT survivors were group-matched on a 1:4 ratio to the reference group by age, sex, and level of education. Regression analyses adjusted for different sets of covariates including demographic, health- and lifestyle-related factors were used to test for differences in cognition between HCT survivors and the reference group resembling the general population. A limited set of clinical characteristics (diagnosis, type of transplant, time since treatment, conditioning regimen with TBI and age at time of transplant) were assessed as potential determinants of neurocognitive dysfunction among HCT survivors. Cognitive impairment was defined as scores in the cognitive domains < -1.5 SD from what can be expected based on someone's age, sex, and education. RESULTS: The mean age at time of transplant was 50.2 (SD 11.2) years, and the mean number of years after transplant was 8.7 (SD 5.7) years. The majority of HCT survivors were treated with autologous HCT (N = 73; 64%). The prevalence of cognitive dysfunction in HCT survivors was 34.8%, and 21.3% in the reference group (p = .002.) When adjusted for age, sex, and level of education HCT survivors had a worse overall cognition score (b=-.35, 95%CI=-.55, -.16, p

Published
2023

3. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Author

DeFilipp, Z, Duarte, R F, Snowden, J A, Majhail, N S, Greenfield, D M, Miranda, J L, Arat, M, Baker, K S, Burns, L J, Duncan, C N, Gilleece, M, Hale, G A, Hamadani, M, Hamilton, B K, Hogan, W J, Hsu, J W, Inamoto, Y, Kamble, R T, Lupo-Stanghellini, M T, Malone, A K, McCarthy, P, Mohty, M, Norkin, M, Paplham, P, Ramanathan, M, Richart, J M, Salooja, N, Schouten, H C, Schoemans, H, Seber, A, Steinberg, A, Wirk, B M, Wood, W A, Battiwalla, M, Flowers, M E D, Savani, B N, and Shaw, B E

Published
2017
Full Text
View/download PDF

4. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

Author

Versluis, J, in ‘t Hout, F E M, Devillier, R, van Putten, W L J, Manz, M G, Vekemans, M -C, Legdeur, M -C, Passweg, J R, Maertens, J, Kuball, J, Biemond, B J, Valk, P J M, van der Reijden, B A, Meloni, G, Schouten, H C, Vellenga, E, Pabst, T, Willemze, R, Löwenberg, B, Ossenkoppele, G, Baron, F, Huls, G, and Cornelissen, J J

Published
2017
Full Text
View/download PDF

6. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Author

Klyuchnikov, E, Bacher, U, Woo Ahn, K, Carreras, J, Kröger, N M, Hari, P N, Ku, G H, Ayala, E, Chen, A I, Chen, Y-B, Cohen, J B, Freytes, C O, Gale, R P, Kamble, R T, Kharfan-Dabaja, M A, Lazarus, H M, Martino, R, Mussetti, A, Savani, B N, Schouten, H C, Usmani, S Z, Wiernik, P H, Wirk, B, Smith, S M, Sureda, A, and Hamadani, M

Published
2016
Full Text
View/download PDF

7. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Author

Uy, G L, Costa, L J, Hari, P N, Zhang, M-J, Huang, J-X, Anderson, K C, Bredeson, C N, Callander, N S, Cornell, R F, Perez, M A D, Dispenzieri, A, Freytes, C O, Gale, R P, Garfall, A, Gertz, M A, Gibson, J, Hamadani, M, Lazarus, H M, Kalaycio, M E, Kamble, R T, Kharfan-Dabaja, M A, Krishnan, A Y, Kumar, S K, Kyle, R A, Landau, H J, Lee, C H, Maiolino, A, Marks, D I, Mark, T M, Munker, R, Nishihori, T, Olsson, R F, Ramanathan, M, Rodriguez, T E, Saad, A A, Savani, B N, Schiller, G J, Schouten, H C, Schriber, J R, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, E A, Tay, J, To, L B, Vesole, D H, Vogl, D T, Wagner, J L, Wirk, B, Wood, W A, and D'Souza, A

Published
2015
Full Text
View/download PDF

9. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

Author

Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, and Löwenberg, B

Published
2015
Full Text
View/download PDF

11. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Author

Bachanova, V, Burns, L J, Wang, T, Carreras, J, Gale, R P, Wiernik, P H, Ballen, K K, Wirk, B, Munker, R, Rizzieri, D A, Chen, Y-B, Gibson, J, Akpek, G, Costa, L J, Kamble, R T, Aljurf, M D, Hsu, J W, Cairo, M S, Schouten, H C, Bacher, U, Savani, B N, Wingard, J R, Lazarus, H M, Laport, G G, Montoto, S, Maloney, D G, Smith, S M, Brunstein, C, and Saber, W

Published
2015
Full Text
View/download PDF

13. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Author

Mohty, M, Hübel, K, Kröger, N, Aljurf, M, Apperley, J, Basak, G W, Bazarbachi, A, Douglas, K, Gabriel, I, Garderet, L, Geraldes, C, Jaksic, O, Kattan, M W, Koristek, Z, Lanza, F, Lemoli, R M, Mendeleeva, L, Mikala, G, Mikhailova, N, Nagler, A, Schouten, H C, Selleslag, D, Suciu, S, Sureda, A, Worel, N, Wuchter, P, Chabannon, C, and Duarte, R F

Published
2014
Full Text
View/download PDF

17. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Author

Labrador, Jorge, Luno, Elisa, Vellenga, Edo, Brunet, Salut, Gonzalez-Campose, Jose, Chillon, Maria C., Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, Gonzalez-Sanmiguel, Jose D., Gil, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de laSerna, Javier, Moreno, Maria-Jose, Perez-Encinas, M., Krsnik, Isabel, Ribera, Josep-Maria, Cervera, Jose, Calasanz, Maria J., Boluda, Blanca, Sobas, Marta, Lowenberg, Bob, Sanz, Miguel A., Montesinos, Pau, Palmer, L., Fernandez, Ciarlo, S., Bezares, F., Rojas, F., Longoni, H., Gelemur, M., Fazio, P., Canepa, C., Saba, S., Balladares, G., Negri, P., Giunta, M., Milone, J., Prates, M., Lafalse, D., Sossa, C., Jaramillo, F., Mayer, J., Ramos, F., Martinez, J., de Groot, M. R., Schouten, H. C., Hematology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Hematologie (9)

Subjects
Male, Cancer Research, complex karyotype, ANTHRACYCLINE MONOCHEMOTHERAPY, medicine.medical_treatment, Abnormal Karyotype, chemotherapy, Gastroenterology, Leukocyte Count, 0302 clinical medicine, Leukemia, Promyelocytic, Acute, Recurrence, Acute promyelocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, PROGNOSTIC-SIGNIFICANCE, Cumulative incidence, ATRA, Child, In Situ Hybridization, Fluorescence, Aged, 80 and over, relapse, PETHEMA, Incidence (epidemiology), ADDITIONAL CHROMOSOME-ABNORMALITIES, Age Factors, Hematology, Middle Aged, Prognosis, ARSENIC TRIOXIDE, FLT3 MUTATIONS, Leukemia, Treatment Outcome, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Female, Adult, medicine.medical_specialty, CYTOGENETIC CHANGES, Adolescent, Young Adult, 03 medical and health sciences, Internal medicine, Statistical significance, Complex Karyotype, medicine, Humans, Clinical significance, Aged, CONSOLIDATION THERAPY, Chromosome Aberrations, Chemotherapy, business.industry, medicine.disease, RISK-ADAPTED TREATMENT, TRANS-RETINOIC ACID, ATRA, Acute promyelocytic leukemia, chemotherapy, complex karyotype, prognostic, relapse, business, prognostic, 030215 immunology
Abstract

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

Published
2019

18. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Author

Sobas, Marta, Montesinos, Pau, Boluda, Blanca, Bernal, Teresa, Vellenga, Edo, Nomdedeu, Josep, Gonzalez-Campos, Jose, Chillon, Maria, Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, David Gonzalez-Sanmiguel, Jose, Gil-Cortes, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de la Serna, Javier, Moreno, Maria-Jose, Perez-Encinas, Manuel, Krsnik, Isabel, Ribera, Josep-Maria, Escoda, Lourdes, Lowenberg, Bob, Angel Sanz, Miguel, Beltran de Heredia, J. M., Hernandez, J. M., Arias, J., Ramos, F., Roman, A., de la Serna, J., Negri, S., Rayon, C., Esteve, J., Fernandez-Calvo, F. J., Diaz-Mediavilla, J., Gil, C., Olave, M., Amutio, E., Pedro, C., Gorosquieta, A., Viguria, M., Zudaire, M., Molero, T., Sayas, M. J., Guardia, R., Martinez, J., de Groot, M. R., Schouten, H. C., Hematology, Radiotherapy, Erasmus MC other, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Hematologie (9)

Subjects
Male, Cancer Research, medicine.medical_treatment, Retinoic acid, CD34, Gene Expression, Kaplan-Meier Estimate, chemotherapy, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, PROGNOSTIC-FACTORS, Leukemia, Promyelocytic, Acute, Recurrence, Acute promyelocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, FAILURE, Anthracyclines, Cumulative incidence, ATRA, Child, CONSOLIDATION, relapse, RISK, Hematology, Middle Aged, Prognosis, CD56 Antigen, Leukemia, Treatment Outcome, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Female, CD56, medicine.medical_specialty, Adolescent, Anthracycline, Tretinoin, Young Adult, 03 medical and health sciences, ADULT, Internal medicine, medicine, Humans, INDICATOR, Aged, Chemotherapy, business.industry, De novo acute, medicine.disease, chemistry, business, prognostic, 030215 immunology
Abstract

Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p

Published
2019

23. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)†

Author

Dietrich, S., Boumendil, A., Finel, H., Avivi, I., Volin, L., Cornelissen, J., Jarosinska, R. J., Schmid, C., Finke, J., Stevens, W. B. C., Schouten, H. C., Kaufmann, M., Sebban, C., Trneny, M., Kobbe, G., Fornecker, L. M., Schetelig, J., Kanfer, E., Heinicke, T., Pfreundschuh, M., Diez-Martin, J. L., Bordessoule, D., Robinson, S., and Dreger, P.

Published
2014
Full Text
View/download PDF

26. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Author

Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J., Hematology laboratory, CCA - Cancer Treatment and quality of life, and Hematology

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

28. Pre-transplant marital status and hematopoietic cell transplantation outcomes

Author

Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., Saber, W., Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., and Saber, W.

Abstract

Background Evidence about the impact of marital status before hematopoietic cell transplantation (HCT) on outcomes after HCT is conflicting. Methods We identified patients 40 years of age and older within the Center for International Blood and Marrow Transplant Research registry who underwent HCT between January 2008 and December 2015. Marital status before HCT was declared as one of: married or living with a partner, single (never married), separated or divorced, and widowed. We performed a multivariable analysis to determine the association of marital status with outcomes after HCT. Results We identified 10,226 allogeneic and 5714 autologous HCT cases with, respectively, a median follow-up of 37 months (range: 1-102 months) and 40 months (range: 1-106 months). No association between marital status and overall survival was observed in either the allogeneic (p = 0.58) or autologous (p = 0.17) setting. However, marital status was associated with grades 2-4 acute graft-versus-host disease (GVHD), p < 0.001, and chronic GVHD, p = 0.04. The risk of grades 2-4 acute GVHD was increased in separated compared with married patients [hazard ratio (FIR): 1.13; 95% confidence interval (CI): 1.03 to 1.24], and single patients had a reduced risk of grades 2-4 acute GVHD (FIR: 0.87; 95% CI: 0.77 to 0.98). The risk of chronic GVHD was lower in widowed compared with married patients (FIR: 0.82; 95% CI: 0.67 to 0.99). Conclusions Overall survival after HCT is not influenced by marital status, but associations were evident between marital status and grades 2-4 acute and chronic GVHD. To better appreciate the effects of marital status and social support, future research should consider using validated scales to measure social support and patient and caregiver reports of caregiver commitment, and to assess health-related quality of life together with health care utilization.

Published
2020
Full Text
View/download PDF

31. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

Author

Tay, J., primary, Beattie, S., additional, Bredeson, C., additional, Brazauskas, R., additional, He, N., additional, Ahmed, I. A., additional, Aljurf, M., additional, Askar, M., additional, Atsuta, Y., additional, Badawy, S., additional, Barata, A., additional, Beitinjaneh, A. M., additional, Bhatt, N. S., additional, Buchbinder, D., additional, Cerny, J., additional, Ciurea, S., additional, D’Souza, A., additional, Dalal, J., additional, Farhadfar, N., additional, Freytes, C. O., additional, Ganguly, S., additional, Gergis, U., additional, Gerull, S., additional, Lazarus, H. M., additional, Hahn, T., additional, Hong, S., additional, Inamoto, Y., additional, Khera, N., additional, Kindwall-Keller, T., additional, Kamble, R. T., additional, Knight, J. M., additional, Koleva, Y. N., additional, Kumar, A., additional, Kwok, J., additional, Murthy, H. S., additional, Olsson, R. F., additional, Angel Diaz-Perez, M., additional, Rizzieri, D., additional, Seo, S., additional, Chhabra, S., additional, Schoemans, H., additional, Schouten, H. C., additional, Steinberg, A., additional, Sullivan, K. M., additional, Szer, J., additional, Szwajcer, D., additional, Ulrickson, M. L., additional, Verdonck, L. F., additional, Wirk, B., additional, Wood, W. A., additional, Yared, J. A., additional, and Saber, W., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results